DK0869785T3 - 4-Hydroxycoumarin-3-carboxyamider til behandling af ikke-insulinafhængig diabetes mellitus - Google Patents
4-Hydroxycoumarin-3-carboxyamider til behandling af ikke-insulinafhængig diabetes mellitusInfo
- Publication number
- DK0869785T3 DK0869785T3 DK96940254T DK96940254T DK0869785T3 DK 0869785 T3 DK0869785 T3 DK 0869785T3 DK 96940254 T DK96940254 T DK 96940254T DK 96940254 T DK96940254 T DK 96940254T DK 0869785 T3 DK0869785 T3 DK 0869785T3
- Authority
- DK
- Denmark
- Prior art keywords
- hydroxycoumarin
- treatment
- diabetes mellitus
- carboxyamides
- insulin
- Prior art date
Links
- -1 4-Hydroxycoumarin-3-carboxyamides Chemical class 0.000 title 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title 1
- OIYXGJMSOBVBQL-UHFFFAOYSA-N 4-hydroxy-2-oxochromene-3-carboxamide Chemical class C1=CC=C2OC(=O)C(C(=O)N)=C(O)C2=C1 OIYXGJMSOBVBQL-UHFFFAOYSA-N 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
- C07D311/56—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 without hydrogen atoms in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
- C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US687895P | 1995-11-17 | 1995-11-17 | |
| US1997696P | 1996-06-17 | 1996-06-17 | |
| PCT/US1996/017122 WO1997018808A1 (en) | 1995-11-17 | 1996-11-12 | 4-hydroxycoumarin-3-carboxamides for the treatment of diabetes mellitus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0869785T3 true DK0869785T3 (da) | 2002-12-16 |
Family
ID=26676192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK96940254T DK0869785T3 (da) | 1995-11-17 | 1996-11-12 | 4-Hydroxycoumarin-3-carboxyamider til behandling af ikke-insulinafhængig diabetes mellitus |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5723476A (da) |
| EP (1) | EP0869785B1 (da) |
| JP (1) | JP2000500490A (da) |
| AT (1) | ATE222762T1 (da) |
| AU (1) | AU7718796A (da) |
| DE (1) | DE69623325T2 (da) |
| DK (1) | DK0869785T3 (da) |
| ES (1) | ES2181923T3 (da) |
| PT (1) | PT869785E (da) |
| WO (1) | WO1997018808A1 (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1506359A (zh) * | 2002-12-05 | 2004-06-23 | �й�ҽѧ��ѧԺҩ���о��� | 新的香豆素酰胺衍生物及其制法和其药物组合物与用途 |
| US20060040876A1 (en) * | 2004-06-10 | 2006-02-23 | Rong-Hwa Lin | Modulation of peroxisome proliferator-activated receptors |
| US20070037193A1 (en) * | 2005-08-12 | 2007-02-15 | Rong-Hwa Lin | Modulation of peroxisome proliferator-activated receptors |
| US20080102137A1 (en) * | 2006-10-31 | 2008-05-01 | Guffey Manning V R | Composition and method for etiological treatment and prevention of diseases and/or complications associated with chronic glucose metabolism destabilization |
| PL2106260T3 (pl) | 2007-01-25 | 2018-06-29 | NAIA Metabolic, Inc. | Środki uwrażliwiające na insulinę i sposoby leczenia |
| KR101133246B1 (ko) | 2010-02-24 | 2012-04-05 | 원광대학교산학협력단 | 신규한 코마린 유도체, 이의 제조방법 및 상기 코마린 유도체를 포함하는 형광 면역측정용 키트 |
| EP2910547B1 (en) | 2012-10-17 | 2017-06-14 | Okayama University | Compound; tautomer and geometric isomer thereof; salt of said compound, tautomer, or geometric isomer; method for manufacturing said compound, tautomer, isomer, or salt; antimicrobial agent; and anti-infective drug |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL111039C (da) * | 1958-10-01 | |||
| US4078075A (en) * | 1976-09-20 | 1978-03-07 | Ciba-Geigy Corporation | Insecticidally active 3-N-(4-trifluoromethylphenyl)-carbamoyl-4-hydroxy-coumarin |
| US4210667A (en) * | 1979-04-19 | 1980-07-01 | Pfizer Inc. | Pharmaceutical preparations containing coumarin carboxylic acid derivatives |
| DE3613065A1 (de) * | 1986-04-18 | 1987-10-29 | Bayer Ag | Verwendung von 3-carbamoyl-4-hydroxy-cumarinen zur bekaempfung von parasitaeren helminthen, neue 3-carbamoyl-4-hydroxy-cumarine und ihre herstellung |
| EP0549729B1 (en) * | 1990-09-07 | 1997-12-17 | Schering Corporation | Antiviral compounds and antihypertensive compounds |
| DK0550493T3 (da) * | 1990-09-28 | 1996-03-11 | Upjohn Co | Anthelmintiske og anticoccidiske 3-carbamoyl-4-hydroxycoumariner, fremgangsmåde til deres anvendelse og sammensætninger |
| US5624951A (en) * | 1992-09-01 | 1997-04-29 | Pfizer Inc. | 4-hydroxy coumarin derivatives with antibacterial activity |
| EP0619314A1 (en) * | 1993-04-09 | 1994-10-12 | Eli Lilly And Company | 4-Phenyl-4H- naphtho(2,1-b)pyran derivatives and their pharmaceutical use |
| DE4337906A1 (de) * | 1993-11-08 | 1995-05-11 | Cassella Ag | Verwendung von Cumarinderivaten |
-
1996
- 1996-11-12 ES ES96940254T patent/ES2181923T3/es not_active Expired - Lifetime
- 1996-11-12 PT PT96940254T patent/PT869785E/pt unknown
- 1996-11-12 WO PCT/US1996/017122 patent/WO1997018808A1/en not_active Ceased
- 1996-11-12 AU AU77187/96A patent/AU7718796A/en not_active Abandoned
- 1996-11-12 DK DK96940254T patent/DK0869785T3/da active
- 1996-11-12 JP JP9519727A patent/JP2000500490A/ja not_active Withdrawn
- 1996-11-12 EP EP96940254A patent/EP0869785B1/en not_active Expired - Lifetime
- 1996-11-12 US US08/747,185 patent/US5723476A/en not_active Expired - Fee Related
- 1996-11-12 DE DE69623325T patent/DE69623325T2/de not_active Expired - Fee Related
- 1996-11-12 AT AT96940254T patent/ATE222762T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| PT869785E (pt) | 2002-12-31 |
| DE69623325D1 (de) | 2002-10-02 |
| WO1997018808A1 (en) | 1997-05-29 |
| EP0869785A1 (en) | 1998-10-14 |
| EP0869785B1 (en) | 2002-08-28 |
| DE69623325T2 (de) | 2003-04-17 |
| US5723476A (en) | 1998-03-03 |
| ATE222762T1 (de) | 2002-09-15 |
| AU7718796A (en) | 1997-06-11 |
| JP2000500490A (ja) | 2000-01-18 |
| ES2181923T3 (es) | 2003-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0833839T3 (da) | Heterocykliske peptidylforbindelser, der er nyttige til behandling af thrombinrelaterede sygdomme | |
| NO976063D0 (no) | Fremgangsmåte for behandling av diabetes | |
| ATE238790T1 (de) | Verwendung von pramipexole als neuroschutzmittel | |
| DE122007000002I2 (de) | Pharmazeutische Zubereitung zur Verwendung in der Behandlung von Diabetes. | |
| DE68902572D1 (de) | Maskieren des geschmacks des thymols. | |
| ATE242213T1 (de) | Neue 4-(oxyalkoxyphenyl)-3-oxy-piperidine zur behandlung von herz- und niereninsuffizienz | |
| ATE369131T1 (de) | Verwendung von agonisten des zentralen cannabinoid-rezeptors cb1 | |
| TR199901174T2 (xx) | Yeni heterosiklilmetil-ikameli pirazol t�revleri. | |
| FI973255A7 (fi) | Karbatsoliyhdisteiden käyttö verentungosta aiheuttavan sydämen toiminnanvajauksen hoidossa | |
| GR960100438A (el) | Νεα παρασιτοκτονα. | |
| BG107537A (bg) | Инхибиране на човешка tnf алфа активност | |
| HUP9800523A2 (hu) | Inzulinszármazékok | |
| UA27911C2 (uk) | Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну | |
| DE69534908D1 (de) | Verwendung von statin zur behandlung von hauterkrankungen | |
| DK0825861T3 (da) | Støddosis chrom-tripicolinat til behandling af type II-diabetes | |
| GB2380939B (en) | Treatment or prevention of auto-immune diseases | |
| DE69510545D1 (de) | Cck oder gastrin modulierende 5-heterocyclicyl-1,5-benzodiazepine | |
| BR9509741A (pt) | Composto e uso de composto | |
| DK0869785T3 (da) | 4-Hydroxycoumarin-3-carboxyamider til behandling af ikke-insulinafhængig diabetes mellitus | |
| DE69805305D1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
| CY1107039T1 (el) | Αναστολεις τριπεπτιδυλ πεπτιδασης | |
| DK89697A (da) | Anvendelse af melatonin til behandling af patienter, der lider af medikamentafhængighed | |
| NO913117D0 (no) | Fremgangsmaate for behandling av benoedeleggende sykdommer. | |
| NO870423L (no) | 5-substituerte oktahydroindolizin-analgetiske forbindelser og 7-keto mellomprodukter. | |
| ATE107165T1 (de) | Verwendung von macrolactonen als antiallergica. |